Regan Sparks, who has cystic fibrosis, takes medication that means she is not eligible for a visa.

The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...

BUFFALO, N.Y. — Nicole Ellis completed her first 5k run in 2020, something that just a short time ago would've seemed almost impossible. "I am currently healthier than I have been in the last ten ...

COLORADO (KCNC) — Some Coloradans are sounding an alarm after learning a state board is considering capping the price of a life-saving drug. They’re worried the move could cause the manufacturer to ...

OMAHA, Nebraska (WPVI) -- A newly-approved drug is bringing hope to many people dealing with cystic fibrosis. CF slowly robs patients of their breathing, choking lungs and other organs with thick ...

- With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - CF affects approximately 3,500 people in Australia. It is ...

Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the med clinched reimbursement in 16 countries ...

- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one ...

Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...